REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
暂无分享,去创建一个
[1] Cesar M. Castro,et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. , 2019, JAMA oncology.
[2] E. Swisher,et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.
[3] B. Monk,et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial , 2019, Gynecologic Oncology.
[4] J. W. Kim,et al. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). , 2019, Gynecologic oncology.
[5] V. Gebski,et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Tinker,et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2 , 2017 .
[7] C. Hudis,et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. , 2017, European journal of cancer.
[8] Jian-Bing Fan,et al. Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes , 2017, Clinical Cancer Research.
[9] R. Wenham,et al. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives , 2016, International journal of women's health.
[10] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.